CSF extracellular vesicles and risk of disease activity after a first demyelinating event

Abstract

Background:

Extracellular vesicles (EVs), a recently described mechanism of cell communication, are released from activated microglial cells and macrophages and are a candidate biomarker in diseases characterized by chronic inflammatory process such as multiple sclerosis (MS).

Methods:

We explored cerebrospinal fluid extracellular vesicle (CSF EV) of myeloid origin (MEVs), cytokine and chemokine levels in patients with clinically isolated syndrome (CIS).

Results:

We found that CSF MEVs were significantly higher in CIS patients than in controls and were inversely correlated to CSF CCL2 levels. MEVs level were significantly associated with an shorter time to evidence of disease activity (hazard ratio: 1.01, 95% confidence interval: 1.00–1.02, p < 0.01) independently from other known prognostic markers.

Conclusion:

After a first demyelinating event, CSF EVs may improve risk stratification of these patients and allow more targeted intervention strategies.

Keywords

Clinically isolated syndrome extracellular vesicles CCL2 cerebrospinal fluid

Get full access to this article

View all access options for this article.

References

Comi

Clinically isolated syndrome: The rationale for early treatment. Nat Clin Pract Neurol 2008; 4(5): 234–235.

Kuhle

Disanto

Dobson

, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multip Scler 2015; 21(8): 1013–1024.

Carandini

Colombo

Finardi

, et al. Microvesicles: What is the role in multiple sclerosis. Front Neurol 2015; 6: 111.

Verderio

Muzio

Turola

, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol 2012; 72(4): 610–624.

Théry

Ostrowski

Segura

Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9(8): 581–593.

Brini

Ruffini

Bergami

, et al. Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss. J Neuroimmunol 2009; 209(1–2): 33–39.

McManus

Berman

Brett

, et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86(1): 20–29.

Franciotta

Martino

Zardini

, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115(1–2): 192–198.

Gschwandtner

Derler

Midwood

KS.

More than just attractive: How CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol 2019; 10: 2759–2729.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB